Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.

The Journal of antimicrobial chemotherapy - 1 Nov 2015

Doyle Tomas, Dunn David T, Ceccherini-Silberstein Francesca, De Mendoza Carmen, Garcia Frederico, Smit Erasmus, Fearnhill Esther, Marcelin Anne-Genevieve, Martinez-Picado Javier, Kaiser Rolf, Geretti Anna Maria

Abstract excerpt

OBJECTIVES: The aim of this study was to characterize the prevalence and patterns of genotypic integrase inhibitor (INI) resistance in relation to HIV-1 clade. METHODS: The cohort comprised 533 INI-naive subjects and 255 raltegravir recipients with viraemia who underwent integrase sequencing in routine care across Europe, including 134/533 (25.1%) and 46/255 (18.0%), respectively, with non-B clades (A, C, D, F,...

Topics

Join the communities discussing this publication.

Anti-HIV Agents
Cohort Studies
Drug Resistance, Viral
Europe
HIV-1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation, Missense

Raltegravir Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 26311843
DOI: 10.1093/jac/dkv243
PMCID: PMC4613743

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.PMID 26311843Read ↗

Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.Semantic proximity Read ↗

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Semantic proximity Read ↗

HIV-1 Integrase Inhibitor Resistance and Its Clinical ImplicationsSemantic proximity Read ↗

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitorsSemantic proximity Read ↗

Resistance to Integrase InhibitorsSemantic proximity Read ↗

Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.Semantic proximity Read ↗

HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.Semantic proximity Read ↗

Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.Semantic proximity Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistanceSemantic proximity Read ↗

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.Semantic proximity Read ↗

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.